J. Goldman & Co LP Has $21.24 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

J. Goldman & Co LP boosted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 17.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 607,499 shares of the company's stock after acquiring an additional 88,883 shares during the quarter. J. Goldman & Co LP owned about 0.38% of Ionis Pharmaceuticals worth $21,238,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Ionis Pharmaceuticals by 9.4% during the 4th quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock valued at $575,880,000 after acquiring an additional 1,416,781 shares in the last quarter. Capital World Investors raised its position in shares of Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock valued at $400,831,000 after acquiring an additional 3,637,041 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Ionis Pharmaceuticals by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 2,687,248 shares of the company's stock valued at $93,976,000 after acquiring an additional 18,890 shares in the last quarter. Norges Bank acquired a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at approximately $59,948,000. Finally, Charles Schwab Investment Management Inc. increased its position in Ionis Pharmaceuticals by 2.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,481,440 shares of the company's stock worth $51,791,000 after buying an additional 38,420 shares during the period. Hedge funds and other institutional investors own 93.86% of the company's stock.

Insider Transactions at Ionis Pharmaceuticals

In related news, Director Michael R. Hayden bought 15,000 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, May 1st. The stock was purchased at an average cost of $31.86 per share, for a total transaction of $477,900.00. Following the acquisition, the director now owns 50,219 shares in the company, valued at $1,599,977.34. This trade represents a 42.59% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Patrick R. O'neil sold 1,207 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $32.35, for a total value of $39,046.45. Following the sale, the executive vice president now directly owns 56,245 shares of the company's stock, valued at $1,819,525.75. The trade was a 2.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 2,027 shares of company stock valued at $62,863 in the last three months. Corporate insiders own 2.60% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IONS. HC Wainwright increased their target price on Ionis Pharmaceuticals from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Redburn Atlantic assumed coverage on Ionis Pharmaceuticals in a research report on Monday, March 31st. They issued a "neutral" rating and a $39.00 target price on the stock. BMO Capital Markets decreased their price target on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research note on Thursday, February 20th. StockNews.com raised Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday, March 18th. Finally, Needham & Company LLC decreased their target price on Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.67.

Ionis Pharmaceuticals Stock Up 0.6%

Ionis Pharmaceuticals stock traded up $0.19 during mid-day trading on Wednesday, hitting $32.72. The company's stock had a trading volume of 59,775 shares, compared to its average volume of 1,561,629. The firm's 50 day moving average is $30.55 and its 200 day moving average is $33.34. The company has a market cap of $5.21 billion, a PE ratio of -10.75 and a beta of 0.15. The company has a debt-to-equity ratio of 2.12, a current ratio of 8.47 and a quick ratio of 8.82. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $52.34.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $132.00 million during the quarter, compared to the consensus estimate of $144.31 million. During the same period last year, the business earned ($0.98) EPS. The business's quarterly revenue was up 10.9% on a year-over-year basis. On average, analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.